Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine the response, disease-free survival, and overall survival of
patients with primary light chain amyloidosis treated with high-dose melphalan and autologous
stem cell transplantation.
II. Determine the toxicity of this regimen in these patients.